PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2564815-0	1989	gamma-Glutamyltranspeptidase-negative phenotypic property of preneoplastic and neoplastic liver lesions induced by ciprofibrate does not change following 2-acetylaminofluorene administration.	ciprofibrate	115-127	gamma-glutamyltransferase 1	Rattus norvegicus	0-28
2611089-4	1989	Under fasting conditions, ciprofibrate, was absorbed rapidly in subjects with normal renal function, and its apparent elimination half-life was approximately 81 h. Both renal clearance (0.15 ml min-1) and cumulative renal excretion (less than 7% of the administered dose) were low.	ciprofibrate	26-38	CD59 molecule (CD59 blood group)	Homo sapiens	194-199
2611089-10	1989	It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1.73 m2.	ciprofibrate	89-101	CD59 molecule (CD59 blood group)	Homo sapiens	181-186
2564815-8	1989	The results of this study suggest that the GGT-negative property of ciprofibrate-induced lesions is stable and not modulatable by AAF.	ciprofibrate	68-80	gamma-glutamyltransferase 1	Rattus norvegicus	43-46
2875789-5	1986	In ciprofibrate-treated animals 52% and 75% of AA were negative for GST-P and GGT, respectively, and 16% was positive for both the enzymes.	ciprofibrate	3-15	glutathione S-transferase pi 1	Rattus norvegicus	68-73
2749133-9	1989	Dot blot analysis of total RNA from livers of ciprofibrate-treated mice (5 strains) showed a significant increase in peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme (PBE) mRNA.	ciprofibrate	46-58	enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase	Mus musculus	202-205
2900680-4	1988	In the ciprofibrate-treated rats, the levels of catalase mRNA increased to less than 2-fold in liver, kidney, intestine, and heart, but no change was detected in other tissues.	ciprofibrate	7-19	catalase	Rattus norvegicus	48-56
3048253-3	1988	Rat hepatocytes cultured with bezafibrate or ciprofibrate (0.1-10 micrograms/ml) for 48 h had increased activities of carnitine acetyltransferase (CAT; 4-6-fold) and carnitine palmitoyltransferase (CPT; 12-34%).	ciprofibrate	45-57	carnitine O-acetyltransferase	Rattus norvegicus	118-145
3048253-3	1988	Rat hepatocytes cultured with bezafibrate or ciprofibrate (0.1-10 micrograms/ml) for 48 h had increased activities of carnitine acetyltransferase (CAT; 4-6-fold) and carnitine palmitoyltransferase (CPT; 12-34%).	ciprofibrate	45-57	carnitine O-acetyltransferase	Rattus norvegicus	147-150
3570161-5	1987	In cultured hepatocytes, ciprofibrate was about 30-fold more active than clofibric acid for the stimulation of carnitine acetyltransferase, laurate hydroxylase and fatty acylCoA oxidase activities.	ciprofibrate	25-37	carnitine O-acetyltransferase	Rattus norvegicus	111-138
3570161-7	1987	The maximal drug-induced increases in carnitine acetyltransferase activity were not additive, and the induction of carnitine acetyltransferase by ciprofibrate was blocked by addition (1 micrograms per ml) of cycloheximide or actinomycin D.	ciprofibrate	146-158	carnitine O-acetyltransferase	Rattus norvegicus	115-142
2875789-5	1986	In ciprofibrate-treated animals 52% and 75% of AA were negative for GST-P and GGT, respectively, and 16% was positive for both the enzymes.	ciprofibrate	3-15	gamma-glutamyltransferase 1	Rattus norvegicus	78-81
19930639-2	2009	The aim of this work was to examine the effect of the PPARalpha agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo) CIII induced hypertriglyceridemia, and its impact on the HDL metabolism.	ciprofibrate	73-85	peroxisome proliferator activated receptor alpha	Mus musculus	54-63
2876121-0	1986	Peroxisome proliferator-induced hepatocarcinogenesis: histochemical analysis of ciprofibrate-induced preneoplastic and neoplastic lesions for gamma-glutamyl transpeptidase activity.	ciprofibrate	80-92	gamma-glutamyltransferase 1	Rattus norvegicus	142-171
2876121-4	1986	The GGT-negative property of these various hepatic preneoplastic and neoplastic lesions persisted at 8 weeks after the withdrawal of ciprofibrate treatment.	ciprofibrate	133-145	gamma-glutamyltransferase 1	Rattus norvegicus	4-7
6867010-3	1983	Liver catalase was elevated after a 2-week treatment with clofibrate (+ 30%), bezafibrate (+71%), and fenofibrate (+77%) at doses of 250 mg/kg/day, and with ciprofibrate (+111%) at 25 mg/kg/day.	ciprofibrate	157-169	catalase	Rattus norvegicus	6-14
26558146-9	2015	Studies in animals have demonstrated the gastric antisecretory activity of PPARalpha agonists like ciprofibrate, bezafibrate and clofibrate.	ciprofibrate	99-111	peroxisome proliferator activated receptor alpha	Rattus norvegicus	75-84
25848047-9	2015	In contrast, treatment of fibroblasts with ciprofibrate or WY14643, PPAR-alpha activators, led to peroxisome proliferation and reduced the TGF-beta-induced myofibroblast differentiation and collagen protein in IPF cells.	ciprofibrate	43-55	peroxisome proliferator activated receptor alpha	Homo sapiens	68-78
25848047-9	2015	In contrast, treatment of fibroblasts with ciprofibrate or WY14643, PPAR-alpha activators, led to peroxisome proliferation and reduced the TGF-beta-induced myofibroblast differentiation and collagen protein in IPF cells.	ciprofibrate	43-55	transforming growth factor beta 1	Homo sapiens	139-147
22476862-10	2012	A single dose of ciprofibrate significantly induces rat liver bilirubin conjugation as well as UGT1A1, UGT1A5 and PPARalpha expression.	ciprofibrate	17-29	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	95-101
22476862-10	2012	A single dose of ciprofibrate significantly induces rat liver bilirubin conjugation as well as UGT1A1, UGT1A5 and PPARalpha expression.	ciprofibrate	17-29	UDP glucuronosyltransferase family 1 member A5	Rattus norvegicus	103-109
22476862-10	2012	A single dose of ciprofibrate significantly induces rat liver bilirubin conjugation as well as UGT1A1, UGT1A5 and PPARalpha expression.	ciprofibrate	17-29	peroxisome proliferator activated receptor alpha	Rattus norvegicus	114-123
21966330-2	2011	Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, and clofibrate act on PPAR alpha to reduce the level of hypertriglyceridemia.	ciprofibrate	60-72	peroxisome proliferator activated receptor alpha	Homo sapiens	96-106
20208394-3	2010	In this study, we examined the effects of PPARalpha agonists (ciprofibrate, bezafibrate, fenofibrate and WY14643) on the expression of CAR and its target gene CYP2B1/2 in rat primary hepatocytes.	ciprofibrate	62-74	peroxisome proliferator activated receptor alpha	Rattus norvegicus	42-51
20208394-3	2010	In this study, we examined the effects of PPARalpha agonists (ciprofibrate, bezafibrate, fenofibrate and WY14643) on the expression of CAR and its target gene CYP2B1/2 in rat primary hepatocytes.	ciprofibrate	62-74	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	135-138
20208394-3	2010	In this study, we examined the effects of PPARalpha agonists (ciprofibrate, bezafibrate, fenofibrate and WY14643) on the expression of CAR and its target gene CYP2B1/2 in rat primary hepatocytes.	ciprofibrate	62-74	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	159-165
20208394-5	2010	Pretreatment of cells with cycloheximide, an inhibitor of protein synthesis, completely suppressed increase in CYP2B1/2 mRNA in response to ciprofibrate, suggesting that protein synthesis is required in this process.	ciprofibrate	140-152	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	111-117
3456610-1	1986	The structurally diverse peroxisome proliferators ciprofibrate, clofibrate, and bis(2-ethylhexyl) phthalate [(EtHx)2 greater than Pht] increase the activities of hepatic catalase and peroxisomal fatty acid beta-oxidation enzymes in conjunction with profound proliferation of peroxisomes in hepatocytes.	ciprofibrate	50-62	catalase	Rattus norvegicus	170-178
6487318-2	1984	Among all the glutathione S-transferases of rat liver, ligandin is maximally inhibited by ciprofibrate.	ciprofibrate	90-102	glutathione S-transferase alpha 2	Rattus norvegicus	55-63
31525465-8	2020	Ciprofibrate also significantly reduced IL-1beta, IL-12p70, IL-17A and IL-18 expression, which are related to airway remodeling, in the sera of CS-exposed rats.	ciprofibrate	0-12	interleukin 1 alpha	Rattus norvegicus	40-48
31525465-8	2020	Ciprofibrate also significantly reduced IL-1beta, IL-12p70, IL-17A and IL-18 expression, which are related to airway remodeling, in the sera of CS-exposed rats.	ciprofibrate	0-12	interleukin 17A	Rattus norvegicus	60-66
31525465-8	2020	Ciprofibrate also significantly reduced IL-1beta, IL-12p70, IL-17A and IL-18 expression, which are related to airway remodeling, in the sera of CS-exposed rats.	ciprofibrate	0-12	interleukin 18	Rattus norvegicus	71-76
25896250-10	2015	Clofibrate, Ciprofibrate, and WY-14643: three agents used for treatment of metabolic disorders, were found to promote PPAR-alpha expression while decreasing miR-17-5p levels and inhibiting steatosis.	ciprofibrate	12-24	peroxisome proliferator activated receptor alpha	Mus musculus	118-128
25896250-10	2015	Clofibrate, Ciprofibrate, and WY-14643: three agents used for treatment of metabolic disorders, were found to promote PPAR-alpha expression while decreasing miR-17-5p levels and inhibiting steatosis.	ciprofibrate	12-24	microRNA 17	Mus musculus	157-163
19930639-13	2009	CONCLUSION: Together these data showed that the PPARalpha agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL.	ciprofibrate	66-78	peroxisome proliferator activated receptor alpha	Mus musculus	48-57
21475872-1	2009	Ciprofibrate is a well-known drug used to normalize lipid parameters and fibrinogen in atherosclerosis patients.	ciprofibrate	0-12	fibrinogen beta chain	Homo sapiens	73-83
18375545-6	2008	Ciprofibrate-induced liver DNA synthesis and growth was absent in PPARalpha-null mice and are PPARalpha dependent.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Mus musculus	66-75
18948393-5	2009	Interestingly, sustained activation of PPARalpha by its hypolipidemic ligand, ciprofibrate, abrogates the adaptive fasting response of PPARalpha during prehibernation and overinduces its target genes, disrupting the prehibernation fattening process.	ciprofibrate	78-90	peroxisome proliferator activated receptor alpha	Homo sapiens	39-48
18948393-5	2009	Interestingly, sustained activation of PPARalpha by its hypolipidemic ligand, ciprofibrate, abrogates the adaptive fasting response of PPARalpha during prehibernation and overinduces its target genes, disrupting the prehibernation fattening process.	ciprofibrate	78-90	peroxisome proliferator activated receptor alpha	Homo sapiens	135-144
18375545-6	2008	Ciprofibrate-induced liver DNA synthesis and growth was absent in PPARalpha-null mice and are PPARalpha dependent.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Mus musculus	94-103
18497086-9	2008	In the presence of the ligand, ciprofibrate, PEDF binding to PPARalpha decreases whereas the presence of troglitazone does not alter PEDF interactions with PPARgamma.	ciprofibrate	31-43	peroxisome proliferator activated receptor alpha	Homo sapiens	61-70
18336980-0	2008	Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate.	ciprofibrate	116-128	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	12-36
18336980-3	2008	Previously we found that the peroxisome proliferator ciprofibrate (CIP) activates NF-kappaB and that dietary vitamin E decreases CIP-induced NF-kappaB DNA binding.	ciprofibrate	53-65	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	82-91
18434116-0	2008	Administration of ciprofibrate to lactating mothers induces PPARalpha-signaling pathway in the liver and kidney of suckling rats.	ciprofibrate	18-30	peroxisome proliferator activated receptor alpha	Rattus norvegicus	60-69
18434116-2	2008	The administration of ciprofibrate to rats during the lactating period determined in their pups significant modifications in hepatic peroxisome enzyme activities, induction of the PPARalpha-target gene, Cyp4a10, and perturbation in cell proliferation and apoptosis, which affected the size of the liver.	ciprofibrate	22-34	peroxisome proliferator activated receptor alpha	Rattus norvegicus	180-189
18434116-2	2008	The administration of ciprofibrate to rats during the lactating period determined in their pups significant modifications in hepatic peroxisome enzyme activities, induction of the PPARalpha-target gene, Cyp4a10, and perturbation in cell proliferation and apoptosis, which affected the size of the liver.	ciprofibrate	22-34	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	203-210
18325492-5	2008	Wild-type AKR1B10-catalyzed carbonyl reduction follows pure non-competitive inhibition kinetics using zopolrestat, EBPC or sorbinil, whereas fenofibrate, Wy 14,643, ciprofibrate and fenofibric acid follow mixed non-competitive inhibition kinetics.	ciprofibrate	165-177	aldo-keto reductase family 1 member B10	Homo sapiens	10-17
18325492-7	2008	Despite these differences, the C299S AKR1B10 mutant still manifests kinetics similar to the wild-type protein with other fibrates including zopolrestat, fenofibrate, Wy 14,346, gemfibrozil and ciprofibrate that show mixed non-competitive inhibition kinetics.	ciprofibrate	193-205	aldo-keto reductase family 1 member B10	Homo sapiens	37-44
17962186-2	2007	We report here that synthetic PPARalpha ligands Wy-14,643, ciprofibrate, clofibrate, and others induce the nuclear translocation of constitutive androstane receptor (CAR) in mouse liver cells in vivo.	ciprofibrate	59-71	peroxisome proliferator activated receptor alpha	Mus musculus	30-39
17951219-4	2008	Treatment with PPARalpha agonists (WY14643, GW7647, and ciprofibrate) significantly increased cardiomyogenesis and expression of the cardiac genes MLC2a, ANP, MHC-beta, MLC2v, and cardiac alpha-actin.	ciprofibrate	56-68	peroxisome proliferator activated receptor alpha	Mus musculus	15-24
17951219-4	2008	Treatment with PPARalpha agonists (WY14643, GW7647, and ciprofibrate) significantly increased cardiomyogenesis and expression of the cardiac genes MLC2a, ANP, MHC-beta, MLC2v, and cardiac alpha-actin.	ciprofibrate	56-68	myosin, light polypeptide 7, regulatory	Mus musculus	147-152
17951219-4	2008	Treatment with PPARalpha agonists (WY14643, GW7647, and ciprofibrate) significantly increased cardiomyogenesis and expression of the cardiac genes MLC2a, ANP, MHC-beta, MLC2v, and cardiac alpha-actin.	ciprofibrate	56-68	myosin, light polypeptide 2, regulatory, cardiac, slow	Mus musculus	169-174
17962186-2	2007	We report here that synthetic PPARalpha ligands Wy-14,643, ciprofibrate, clofibrate, and others induce the nuclear translocation of constitutive androstane receptor (CAR) in mouse liver cells in vivo.	ciprofibrate	59-71	nuclear receptor subfamily 1, group I, member 3	Mus musculus	132-164
17962186-2	2007	We report here that synthetic PPARalpha ligands Wy-14,643, ciprofibrate, clofibrate, and others induce the nuclear translocation of constitutive androstane receptor (CAR) in mouse liver cells in vivo.	ciprofibrate	59-71	nuclear receptor subfamily 1, group I, member 3	Mus musculus	166-169
17962186-7	2007	Both Wy-14,643 and ciprofibrate occupied the ligand binding pocket of CAR and adapted a binding mode similar to that of the CAR inverse agonist androstenol.	ciprofibrate	19-31	nuclear receptor subfamily 1, group I, member 3	Mus musculus	70-73
17962186-7	2007	Both Wy-14,643 and ciprofibrate occupied the ligand binding pocket of CAR and adapted a binding mode similar to that of the CAR inverse agonist androstenol.	ciprofibrate	19-31	nuclear receptor subfamily 1, group I, member 3	Mus musculus	124-127
17234604-0	2007	P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation.	ciprofibrate	59-71	peroxisome proliferator activated receptor alpha	Rattus norvegicus	80-89
18497086-9	2008	In the presence of the ligand, ciprofibrate, PEDF binding to PPARalpha decreases whereas the presence of troglitazone does not alter PEDF interactions with PPARgamma.	ciprofibrate	31-43	serpin family F member 1	Homo sapiens	45-49
17234604-6	2007	Based on these results, we propose that HEETs may serve as endogenous PPARalpha ligands and that the P450 AA monooxygenases participate in ciprofibrate-induced peroxisomal proliferation and the activation of PPARalpha downstream targets.	ciprofibrate	139-151	peroxisome proliferator activated receptor alpha	Rattus norvegicus	208-217
16434500-2	2006	We previously showed that peroxisome proliferators increase NF-kappaB DNA binding activity in rats, mice, and hepatoma cell lines, and that mice deficient in the p50 subunit of NF-kappaB had much lower cell proliferation in response to the peroxisome proliferator ciprofibrate.	ciprofibrate	264-276	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	162-186
16337773-3	2006	Ciprofibrate caused a marked inhibition of testicular 3beta-hydroxysteroid dehydrogenase-isomerase (3beta-HSD) activity that was significant after 3 days and subsequently decreased to 40% of control level.	ciprofibrate	0-12	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	54-98
16337773-3	2006	Ciprofibrate caused a marked inhibition of testicular 3beta-hydroxysteroid dehydrogenase-isomerase (3beta-HSD) activity that was significant after 3 days and subsequently decreased to 40% of control level.	ciprofibrate	0-12	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	100-109
16337773-4	2006	Ciprofibrate treatment also reduced 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity to a lesser extent but had no effect on 17-hydroxylase (17-OHase) activity.	ciprofibrate	0-12	aldo-keto reductase family 1, member C12	Rattus norvegicus	36-71
16337773-4	2006	Ciprofibrate treatment also reduced 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity to a lesser extent but had no effect on 17-hydroxylase (17-OHase) activity.	ciprofibrate	0-12	aldo-keto reductase family 1, member C12	Rattus norvegicus	73-83
16337773-6	2006	Furthermore, in addition to the enzyme-specific effect of ciprofibrate on 3beta-HSD in the testes, a tissue-specific effect was also evident, since no significant effects of ciprofibrate were seen on the activities of 3beta-HSD or 21-OHase in the adrenal glands from the same animals.	ciprofibrate	58-70	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	74-83
16554032-1	2006	Ciprofibrate, a potent peroxisome proliferator, induces pleiotropic responses in liver by activating peroxisome proliferator-activated receptor alpha (PPARalpha), a nuclear receptor.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Homo sapiens	151-160
16554032-3	2006	SDS-PAGE and matrix-assisted laser desorption/ionization reflection time-of-flight mass spectrometric analyses of ciprofibrate-binding proteins from liver nuclear extracts obtained using ciprofibrate-Sepharose affinity matrix resulted in the identification of a new high molecular weight nuclear receptor coactivator, which we designated PRIC320.	ciprofibrate	114-126	chromodomain helicase DNA binding protein 9	Homo sapiens	338-345
16081524-1	2005	Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists that have been in clinical use for many decades for treatment of dyslipidemia.	ciprofibrate	18-30	peroxisome proliferator-activated receptor alpha	Macaca fascicularis	65-113
16562643-0	2006	[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].	ciprofibrate	88-100	fibrinogen beta chain	Homo sapiens	33-43
16099866-0	2005	Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha.	ciprofibrate	0-12	gastrin	Rattus norvegicus	28-35
16099866-0	2005	Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Rattus norvegicus	81-91
16099866-1	2005	The lipid-lowering drug ciprofibrate stimulates gastrin-producing cells in the rat stomach without lowering gastric acidity.	ciprofibrate	24-36	gastrin	Rattus norvegicus	48-55
16099866-9	2005	In contrast, ciprofibrate induced hypergastrinemia, a 50% increase in G cell density, and a threefold increase in gastrin mRNA in sham-operated rats.	ciprofibrate	13-25	gastrin	Rattus norvegicus	39-46
16099866-12	2005	In WT mice, ciprofibrate induced hypergastrinemia, a doubling of G cell density, and a threefold increase in gastrin mRNA.	ciprofibrate	12-24	gastrin	Mus musculus	38-45
16226225-1	2005	Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia.	ciprofibrate	59-71	peroxisome proliferator activated receptor alpha	Homo sapiens	105-153
16226225-1	2005	Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia.	ciprofibrate	59-71	peroxisome proliferator activated receptor alpha	Homo sapiens	155-164
16081524-1	2005	Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists that have been in clinical use for many decades for treatment of dyslipidemia.	ciprofibrate	18-30	peroxisome proliferator-activated receptor alpha	Macaca fascicularis	115-124
15123680-0	2004	The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.	ciprofibrate	73-85	peroxisome proliferator activated receptor alpha	Mus musculus	4-52
15919853-9	2005	Two PXR ligands [pregnenolone-16alpha-carbonitrile (PCN) and spironolactone] increased Oatp1a4 mRNA expression in liver, whereas PXR ligands (PCN, spironolactone, and dexamethasone) and PPARalpha ligands (clofibrate, ciprofibrate, and diethylhexylphthalate) decreased Oatp1a1, 1b2, 2a1, and 2b1 mRNA expression in liver.	ciprofibrate	217-229	nuclear receptor subfamily 1, group I, member 2	Mus musculus	4-7
15968640-4	2005	Our studies demonstrated that the PPAR-alpha agonists ciprofibrate, fenofibrate, gemfibrozil, and WY 14,643 each inhibited NO production by cytokine-stimulated microglia in a dose-dependent manner.	ciprofibrate	54-66	peroxisome proliferator activated receptor alpha	Mus musculus	34-44
15833929-8	2005	Mrp3 was also induced by two other CAR activators phenobarbital and diallyl sulfide, two PXR ligands, pregnenalone-16alpha-carbonitrile and spironolactone, and the PPARalpha ligands clofibrate, ciprofibrate, and diethylhexylphthalate.	ciprofibrate	194-206	prolactin family 2, subfamily c, member 4	Mus musculus	0-4
15635043-2	2005	The treatment of primary cultured human hepatocytes with a peroxisome proliferator-activated receptor alpha (PPARalpha)-activating concentration of ciprofibrate (10(-) (4) M) increased (HUMAN)SULT2A1 mRNA, immunoreactive protein, and enzymatic activity levels by approximately 2-fold.	ciprofibrate	148-160	peroxisome proliferator activated receptor alpha	Homo sapiens	59-107
15635043-2	2005	The treatment of primary cultured human hepatocytes with a peroxisome proliferator-activated receptor alpha (PPARalpha)-activating concentration of ciprofibrate (10(-) (4) M) increased (HUMAN)SULT2A1 mRNA, immunoreactive protein, and enzymatic activity levels by approximately 2-fold.	ciprofibrate	148-160	peroxisome proliferator activated receptor alpha	Homo sapiens	109-118
15635043-2	2005	The treatment of primary cultured human hepatocytes with a peroxisome proliferator-activated receptor alpha (PPARalpha)-activating concentration of ciprofibrate (10(-) (4) M) increased (HUMAN)SULT2A1 mRNA, immunoreactive protein, and enzymatic activity levels by approximately 2-fold.	ciprofibrate	148-160	sulfotransferase family 2A member 1	Homo sapiens	192-199
15177943-2	2004	Treatment of rats with the PPARalpha ligand ciprofibrate increases serum gastrin concentrations, and several lines of evidence suggest that non-amidated gastrins act as growth factors for the colonic mucosa.	ciprofibrate	44-56	peroxisome proliferator activated receptor alpha	Rattus norvegicus	27-36
15177943-2	2004	Treatment of rats with the PPARalpha ligand ciprofibrate increases serum gastrin concentrations, and several lines of evidence suggest that non-amidated gastrins act as growth factors for the colonic mucosa.	ciprofibrate	44-56	gastrin	Rattus norvegicus	73-80
15177943-6	2004	Similar increases in progastrin were seen following treatment with the PPARalpha ligands ciprofibrate and fenofibrate, but not with bezafibrate, gemfibrozil or Wy 14643.	ciprofibrate	89-101	peroxisome proliferator activated receptor alpha	Homo sapiens	71-80
16162440-7	2005	The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4%), fibrinogen, IL-1alpha, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level.	ciprofibrate	42-54	fibrinogen beta chain	Homo sapiens	132-142
16162440-7	2005	The much larger improvement of FMD due to ciprofibrate therapy was accompanied by significant reductions of cholesterol (by 14.4%), fibrinogen, IL-1alpha, and sICAM levels and by significant increase of high-density lipoprotein (HDL) cholesterol concentration, but the change in FMD correlated only with the reduction of the cholesterol level.	ciprofibrate	42-54	interleukin 1 alpha	Homo sapiens	144-153
15123680-6	2004	After 150 days of treatment with ciprofibrate, consistent with the increased plasma accumulation of apoB-100-carrying IDL and LDL, the LDLR-deficient mice displayed severe atherosclerotic lesions in the aorta.	ciprofibrate	33-45	apolipoprotein B	Mus musculus	100-108
15123680-6	2004	After 150 days of treatment with ciprofibrate, consistent with the increased plasma accumulation of apoB-100-carrying IDL and LDL, the LDLR-deficient mice displayed severe atherosclerotic lesions in the aorta.	ciprofibrate	33-45	low density lipoprotein receptor	Mus musculus	135-139
15123680-7	2004	These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	73-77
15123680-7	2004	These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	154-162
15123680-0	2004	The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.	ciprofibrate	73-85	peroxisome proliferator activated receptor alpha	Mus musculus	54-63
15123680-0	2004	The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.	ciprofibrate	73-85	apolipoprotein B	Mus musculus	95-111
15123680-0	2004	The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.	ciprofibrate	73-85	low density lipoprotein receptor	Mus musculus	128-160
15123680-2	2004	Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels.	ciprofibrate	38-50	low density lipoprotein receptor	Mus musculus	13-17
15123680-2	2004	Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels.	ciprofibrate	38-50	apolipoprotein B	Mus musculus	86-93
15123680-2	2004	Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels.	ciprofibrate	38-50	apolipoprotein B	Mus musculus	189-197
15309245-9	2004	Furthermore, ciprofibrate induced an increase by 26% in HDL-associated PAF-AH activity (P =.004) along with an increase in serum HDL-cholesterol levels (P =.02).	ciprofibrate	13-25	phospholipase A2 group VII	Homo sapiens	71-77
15226458-4	2004	Cells were exposed to TNF-alpha for 2 h following pretreament with the PPARalpha agonists fenofibrate or ciprofibrate or the PPARgamma agonists thiazolidinedione or troglitazone.	ciprofibrate	105-117	tumor necrosis factor	Homo sapiens	22-31
15309245-8	2004	In contrast, treatment with fluvastatin (40 mg, n = 50) or ciprofibrate (100 mg, n = 40) reduced by 25% plasma PAF-AH activity (P <.001) associated with a decrease in serum levels of total cholesterol and LDL-cholesterol (P <.001).	ciprofibrate	59-71	phospholipase A2 group VII	Homo sapiens	111-117
15100326-3	2004	The PPAR alpha agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia.	ciprofibrate	38-50	peroxisome proliferator activated receptor alpha	Homo sapiens	4-14
14570884-2	2003	Treatment of apoE-deficient mice with ciprofibrate or other peroxisome proliferator-activated receptor alpha agonists severely aggravates their hypercholesterolemia by interfering with one or more mechanisms of remnant removal from the circulation that do not require mediation by apoE (Fu, T., Kashireddy, P., and Borensztajn, J.	ciprofibrate	38-50	apolipoprotein E	Mus musculus	13-17
14570884-2	2003	Treatment of apoE-deficient mice with ciprofibrate or other peroxisome proliferator-activated receptor alpha agonists severely aggravates their hypercholesterolemia by interfering with one or more mechanisms of remnant removal from the circulation that do not require mediation by apoE (Fu, T., Kashireddy, P., and Borensztajn, J.	ciprofibrate	38-50	apolipoprotein E	Mus musculus	281-285
14570884-6	2003	In the present investigation we report that ciprofibrate treatment causes the down-regulation of hepatic scavenger receptor class B, type I (SR-BI) protein expression in the livers of apoE-deficient mice.	ciprofibrate	44-56	scavenger receptor class B, member 1	Mus musculus	105-139
14570884-6	2003	In the present investigation we report that ciprofibrate treatment causes the down-regulation of hepatic scavenger receptor class B, type I (SR-BI) protein expression in the livers of apoE-deficient mice.	ciprofibrate	44-56	scavenger receptor class B, member 1	Mus musculus	141-146
14570884-6	2003	In the present investigation we report that ciprofibrate treatment causes the down-regulation of hepatic scavenger receptor class B, type I (SR-BI) protein expression in the livers of apoE-deficient mice.	ciprofibrate	44-56	apolipoprotein E	Mus musculus	184-188
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	35-47	scavenger receptor class B, member 1	Mus musculus	15-20
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	35-47	apolipoprotein E	Mus musculus	56-60
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	35-47	apolipoprotein B	Mus musculus	172-179
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	130-142	scavenger receptor class B, member 1	Mus musculus	15-20
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	130-142	apolipoprotein E	Mus musculus	56-60
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	130-142	apolipoprotein B	Mus musculus	172-179
14570884-9	2003	We also report that remnants isolated from the plasma of ciprofibrate-treated apoE-deficient mice bind to murine SR-BI expressed in stably transfected cultured cells.	ciprofibrate	57-69	apolipoprotein E	Mus musculus	78-82
14570884-9	2003	We also report that remnants isolated from the plasma of ciprofibrate-treated apoE-deficient mice bind to murine SR-BI expressed in stably transfected cultured cells.	ciprofibrate	57-69	scavenger receptor class B, member 1	Mus musculus	113-118
12785120-1	2003	An open problem of the lipid lowering agent ciprofibrate (rac-2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid, CAS 52214-84-3) is its metabolism concerning the conjugation with amino acids and glucuronic acid.	ciprofibrate	44-56	Rac family small GTPase 2	Homo sapiens	58-63
12851464-1	2003	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents.	ciprofibrate	42-54	peroxisome proliferator activated receptor alpha	Rattus norvegicus	68-116
12851464-1	2003	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents.	ciprofibrate	42-54	peroxisome proliferator activated receptor alpha	Rattus norvegicus	118-127
12851464-4	2003	Ciprofibrate changed the expression of many genes including previously known PPARalpha agonist-responsive genes involved in processes such as lipid metabolism and inflammatory responses.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Rattus norvegicus	77-86
12713444-9	2003	These results indicate that the ciprofibrate-induced accumulation of apoB-48-carrying remnants in apoE-deficient mice is caused by the inhibition of an as yet uncharacterized apoE-independent mechanism of removal of remnant from the circulation by the liver.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	69-76
12713444-9	2003	These results indicate that the ciprofibrate-induced accumulation of apoB-48-carrying remnants in apoE-deficient mice is caused by the inhibition of an as yet uncharacterized apoE-independent mechanism of removal of remnant from the circulation by the liver.	ciprofibrate	32-44	apolipoprotein E	Mus musculus	98-102
12713444-9	2003	These results indicate that the ciprofibrate-induced accumulation of apoB-48-carrying remnants in apoE-deficient mice is caused by the inhibition of an as yet uncharacterized apoE-independent mechanism of removal of remnant from the circulation by the liver.	ciprofibrate	32-44	apolipoprotein E	Mus musculus	175-179
12915663-7	2003	In conclusion, the action of ciprofibrate in type IIB dyslipidemia leads to preferential reduction in particle numbers of atherogenic VLDL-1, VLDL-2, and dense LDL and, concomitantly, to elevation in HDL-3 levels that are associated with stimulation of HDL-mediated cellular free cholesterol efflux through the scavenger receptor class B, type I receptor pathway.	ciprofibrate	29-41	HDL3	Homo sapiens	200-205
12658348-2	2003	The peroxisome proliferator-activated receptor (PPAR) alpha-agonist ciprofibrate is used as a lipid-lowering drug.	ciprofibrate	68-80	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-46
12658348-2	2003	The peroxisome proliferator-activated receptor (PPAR) alpha-agonist ciprofibrate is used as a lipid-lowering drug.	ciprofibrate	68-80	peroxisome proliferator activated receptor alpha	Rattus norvegicus	48-52
12883078-4	2003	NF-kappaB DNA binding activity was present and increased after ciprofibrate treatment in wild-type mice, but was not detected in p50-/- mice.	ciprofibrate	63-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-9
12883078-6	2003	However, the increase in proliferation was greater in ciprofibrate-fed wild-type mice than in ciprofibrate-fed p50-/- mice.	ciprofibrate	94-106	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	111-114
12883078-9	2003	The c-Jun and JunB mRNA levels were higher in untreated p50-/- mice than in untreated control mice; c-Jun mRNA levels increased, whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.	ciprofibrate	185-197	jun proto-oncogene	Mus musculus	4-9
12883078-9	2003	The c-Jun and JunB mRNA levels were higher in untreated p50-/- mice than in untreated control mice; c-Jun mRNA levels increased, whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.	ciprofibrate	185-197	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-59
12883078-9	2003	The c-Jun and JunB mRNA levels were higher in untreated p50-/- mice than in untreated control mice; c-Jun mRNA levels increased, whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.	ciprofibrate	185-197	jun proto-oncogene	Mus musculus	100-105
12883078-9	2003	The c-Jun and JunB mRNA levels were higher in untreated p50-/- mice than in untreated control mice; c-Jun mRNA levels increased, whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.	ciprofibrate	185-197	jun B proto-oncogene	Mus musculus	137-141
12883078-12	2003	These data indicate that NF-kappaB contributes to the proliferative and apoptotic changes that occur in the liver in response to ciprofibrate.	ciprofibrate	129-141	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	25-34
12649303-4	2003	We demonstrated that both PPAR alpha (clofibrate and ciprofibrate) and PPAR gamma ligands (troglitazone and 15 deoxy-prostaglandin J2, 15d-PGJ2) inhibited growth, induced the onset of monocytic-like differentiation, and increased the proportion of G0/G1 cells in the HL-60 leukemic cell line.	ciprofibrate	53-65	peroxisome proliferator activated receptor alpha	Homo sapiens	26-36
12649303-7	2003	Clofibrate (50 microM), ciprofibrate (50 microM), and 15d-PGJ2 (2.5 microM) inhibited c-myb and cyclin D2 expression, whereas they did not affect c-myc and cyclin D1 expression.	ciprofibrate	24-36	MYB proto-oncogene, transcription factor	Homo sapiens	86-91
12649303-7	2003	Clofibrate (50 microM), ciprofibrate (50 microM), and 15d-PGJ2 (2.5 microM) inhibited c-myb and cyclin D2 expression, whereas they did not affect c-myc and cyclin D1 expression.	ciprofibrate	24-36	cyclin D2	Homo sapiens	96-105
12771043-4	2003	Our results show that HCCs developing in AOX-/- mice share a number of deregulated (up- or down-regulated) genes with ciprofibrate-induced liver tumors.	ciprofibrate	118-130	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	41-44
12771043-5	2003	The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.	ciprofibrate	57-69	peroxisome proliferator activated receptor alpha	Mus musculus	162-171
12771043-5	2003	The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.	ciprofibrate	57-69	peroxisome proliferator activated receptor alpha	Mus musculus	176-185
12771043-5	2003	The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.	ciprofibrate	321-333	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	46-52
12771043-5	2003	The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.	ciprofibrate	321-333	peroxisome proliferator activated receptor alpha	Mus musculus	162-171
12771043-5	2003	The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.	ciprofibrate	321-333	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	46-49
12381268-5	2003	Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced.	ciprofibrate	38-50	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	104-108
12381268-5	2003	Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced.	ciprofibrate	38-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	120-125
12381268-5	2003	Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced.	ciprofibrate	38-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-145
12381268-5	2003	Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced.	ciprofibrate	38-50	solute carrier organic anion transporter family, member 1a1	Mus musculus	198-203
12785120-1	2003	An open problem of the lipid lowering agent ciprofibrate (rac-2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid, CAS 52214-84-3) is its metabolism concerning the conjugation with amino acids and glucuronic acid.	ciprofibrate	44-56	BCAR1 scaffold protein, Cas family member	Homo sapiens	126-129
12163133-7	2002	This suggests that ciprofibrate and gemfibrozil induce a different conformation to the receptor-PGC-1 and receptor-CBP complex, respectively.	ciprofibrate	19-31	PPARG coactivator 1 alpha	Homo sapiens	96-101
12354675-2	2002	Ciprofibrate is a specific ligand for the nuclear peroxisome proliferator-activated receptor alpha (PPAR alpha).	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Rattus norvegicus	50-98
12354675-2	2002	Ciprofibrate is a specific ligand for the nuclear peroxisome proliferator-activated receptor alpha (PPAR alpha).	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Rattus norvegicus	100-110
12354675-7	2002	Ciprofibrate and WY-14643 altered the levels of acyl CoA-oxidase mRNA and PPAR alpha mRNA in antrum, but had no effect in corpus.	ciprofibrate	0-12	peroxisome proliferator activated receptor alpha	Rattus norvegicus	74-84
12189208-3	2002	Here we report the identification of such a transcriptionally active PPAR alpha-interacting cofactor (PRIC) complex from rat liver nuclear extracts that interacts with full-length PPAR alpha in the presence of ciprofibrate, a synthetic ligand, and leukotriene B(4), a natural ligand.	ciprofibrate	210-222	peroxisome proliferator activated receptor alpha	Rattus norvegicus	69-79
12189208-3	2002	Here we report the identification of such a transcriptionally active PPAR alpha-interacting cofactor (PRIC) complex from rat liver nuclear extracts that interacts with full-length PPAR alpha in the presence of ciprofibrate, a synthetic ligand, and leukotriene B(4), a natural ligand.	ciprofibrate	210-222	peroxisome proliferator activated receptor alpha	Rattus norvegicus	180-190
12055195-6	2002	Constructs containing this element were transactivated by WY14643 and ciprofibrate, ligands of the peroxisome proliferator-activated receptor alpha (PPARalpha), in Caco2 cells.	ciprofibrate	70-82	peroxisome proliferator activated receptor alpha	Homo sapiens	99-147
12055195-6	2002	Constructs containing this element were transactivated by WY14643 and ciprofibrate, ligands of the peroxisome proliferator-activated receptor alpha (PPARalpha), in Caco2 cells.	ciprofibrate	70-82	peroxisome proliferator activated receptor alpha	Homo sapiens	149-158
12163133-7	2002	This suggests that ciprofibrate and gemfibrozil induce a different conformation to the receptor-PGC-1 and receptor-CBP complex, respectively.	ciprofibrate	19-31	CREB binding protein	Homo sapiens	115-118
12025914-0	2002	Effect of ciprofibrate on C-reactive protein and fibrinogen levels.	ciprofibrate	10-22	C-reactive protein	Homo sapiens	26-44
12025914-0	2002	Effect of ciprofibrate on C-reactive protein and fibrinogen levels.	ciprofibrate	10-22	fibrinogen beta chain	Homo sapiens	49-59
11770837-9	2001	Compared with the control subjects (2.91 +/- 0.35 g/l), fibrinogen levels before treatment were higher in patients with dyslipidemia treated with ciprofibrate (3.42 +/- 0.59 g/l, NS) and fenofibrate (3.65 +/- 1.10 g/l, p < 0.05).	ciprofibrate	146-158	fibrinogen beta chain	Homo sapiens	56-66
11985831-4	2002	Using the sensitive and discriminatory RNase protection co-assay, we demonstrate that both ciprofibrate and valproate induce mHS expression in liver, the archetypal PPAR alpha-expressing organ.	ciprofibrate	91-103	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2	Mus musculus	125-128
11985831-4	2002	Using the sensitive and discriminatory RNase protection co-assay, we demonstrate that both ciprofibrate and valproate induce mHS expression in liver, the archetypal PPAR alpha-expressing organ.	ciprofibrate	91-103	peroxisome proliferator activated receptor alpha	Rattus norvegicus	165-175
11985831-5	2002	Furthermore, ciprofibrate potently increases mHS mRNA abundance in rat brain, together with lesser increases in two other PPAR alpha-regulated mRNAs.	ciprofibrate	13-25	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2	Mus musculus	45-48
12073774-10	2002	The results of these studies clearly demonstrate that the severity of CDD-induced fatty change and hepatitis in rats can be rapidly decreased by ciprofibrate and suggest the therapeutic potential of PPAR alpha ligands in the treatment of nonalcoholic steatohepatitis in humans to rapidly reverse liver changes.	ciprofibrate	145-157	peroxisome proliferator activated receptor alpha	Rattus norvegicus	199-209
11827749-2	2002	In this study we demonstrate that PPAR-alpha ligands (clofibrate and ciprofibrate) and PPAR-gamma ligands (troglitazone and 15d-prostaglandin J2) inhibit growth and induce monocytic differentiation in HL-60 cells, whereas only PPAR-gamma ligands inhibit growth of U937 cells.	ciprofibrate	69-81	peroxisome proliferator activated receptor alpha	Homo sapiens	34-44
11716462-6	2001	MLCL1 transiently expressed in COS-7 cells activated nafenopin (C(50) 192.9 microM), ciprofibrate (C(50) 168.7 microM), and palmitic acid (C(50) 4.5 microM) to their respective CoA conjugates.	ciprofibrate	85-97	long-chain-fatty-acid--CoA ligase 1	Callithrix jacchus	0-5
11770837-10	2001	One-month ciprofibrate treatment resulted in an insignificant decrease in PAI-1 levels (76.28 21.60 ng/ml, NS) and in a significant decrease in fibrinogen levels (2.73 +/- 0.40 g/l, p < 0.01).	ciprofibrate	10-22	serpin family E member 1	Homo sapiens	74-79
11770837-10	2001	One-month ciprofibrate treatment resulted in an insignificant decrease in PAI-1 levels (76.28 21.60 ng/ml, NS) and in a significant decrease in fibrinogen levels (2.73 +/- 0.40 g/l, p < 0.01).	ciprofibrate	10-22	fibrinogen beta chain	Homo sapiens	144-154
11701475-4	2001	Ciprofibrate and the PPARalpha agonist Wy14,643 decreased bile acid synthesis in cultured rat hepatocytes and suppressed cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities, paralleled by a similar reduction of the respective mRNAs.	ciprofibrate	0-12	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	121-151
11701475-4	2001	Ciprofibrate and the PPARalpha agonist Wy14,643 decreased bile acid synthesis in cultured rat hepatocytes and suppressed cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities, paralleled by a similar reduction of the respective mRNAs.	ciprofibrate	0-12	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	156-177
11367862-10	2001	The ciprofibrate was suspended after the 8th week for a 4 weeks period and the triglyceride and the fibrinogen levels increased whereas the HDL cholesterol level decreased significantly.	ciprofibrate	4-16	fibrinogen beta chain	Homo sapiens	100-110
10812581-5	2000	Our aim was to evaluate the efficacy and safety of ciprofibrate in improving dyslipoproteinemia and its effect on fibrinogen plasma concentrations, carbohydrate metabolism variations and insulin action.	ciprofibrate	51-63	fibrinogen beta chain	Homo sapiens	114-124
10860941-10	2000	We also provide evidence of the translocation of PPARalpha from the cytosol to the nucleus upon activation by ciprofibrate.	ciprofibrate	110-122	peroxisome proliferator activated receptor alpha	Homo sapiens	49-58
11071880-6	2000	After PPAR alpha activation with ciprofibrate, both mitochondrial and peroxisomal beta-oxidation enzymes were induced, with the strongest response seen in the liver, a moderate response in the kidney, and no significant response in the heart.	ciprofibrate	33-45	peroxisome proliferator activated receptor alpha	Homo sapiens	6-16
10915223-11	2000	Ciprofibrate stimulates gastrin cell activity by a mechanism unaffected by octreotide, but octreotide does inhibit basal and gastrin-stimulated ECL cell function and growth.	ciprofibrate	0-12	gastrin	Rattus norvegicus	24-31
10892727-7	2000	Administration of dexamethasone to mice in combination with ciprofibrate produced expression of the acidic SBP2 at 23% of the control level and the basic SBP2 at 36%, a slightly moderated reduction compared with the decrease that occurred with ciprofibrate alone.	ciprofibrate	60-72	SECIS binding protein 2	Mus musculus	107-111
10892727-7	2000	Administration of dexamethasone to mice in combination with ciprofibrate produced expression of the acidic SBP2 at 23% of the control level and the basic SBP2 at 36%, a slightly moderated reduction compared with the decrease that occurred with ciprofibrate alone.	ciprofibrate	60-72	SECIS binding protein 2	Mus musculus	154-158
10892727-8	2000	These data suggest that peroxisome proliferators such as ciprofibrate cause a decrease in the abundance of the SBP2, which leads to increased cell proliferation, even in the presence of an inhibitor such as dexamethasone.	ciprofibrate	57-69	SECIS binding protein 2	Mus musculus	111-115
10812581-5	2000	Our aim was to evaluate the efficacy and safety of ciprofibrate in improving dyslipoproteinemia and its effect on fibrinogen plasma concentrations, carbohydrate metabolism variations and insulin action.	ciprofibrate	51-63	insulin	Homo sapiens	187-194
10812581-16	2000	CONCLUSIONS: Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action.	ciprofibrate	13-25	fibrinogen beta chain	Homo sapiens	110-120
10812581-16	2000	CONCLUSIONS: Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action.	ciprofibrate	13-25	insulin	Homo sapiens	202-209
10941600-0	2000	Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.	ciprofibrate	131-143	apolipoprotein A1	Homo sapiens	27-61
10941600-5	2000	We found that ciprofibrate administration enhanced production of apoA-I and paraoxonase transport capacity.	ciprofibrate	14-26	apolipoprotein A1	Homo sapiens	65-71
10497143-8	1999	UGT1A8, but not UGT1A10, catalyzed the glucuronidation of opioids, bile acids, fatty acids, retinoids, and clinically useful drugs, such as ciprofibrate, furosemide, and diflunisal.	ciprofibrate	140-152	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	0-6
10485318-4	1999	Furthermore, the MnSOD level in peroxisomes was modulated by oxidative stress conditions such as ischemia-reperfusion or the treatment with ciprofibrate, a peroxisomal proliferator.	ciprofibrate	140-152	superoxide dismutase 2	Rattus norvegicus	17-22
10502499-3	1999	In rat hepatocyte cultures, after 72 h of treatment with the various PPs at 100-500 microM, a compound-dependent increase in acyl CoA oxidase (ACO) and carnitine acetyl transferase (CAT) activities, markers of peroxisome proliferation, was observed with the following potencies: CIPRO = NAFE > BEZA > CLO > DEHP.	ciprofibrate	279-284	carnitine O-acetyltransferase	Rattus norvegicus	182-185
10509752-0	1999	Phosphorylation of peroxisome proliferator-activated receptor alpha in rat Fao cells and stimulation by ciprofibrate.	ciprofibrate	104-116	peroxisome proliferator activated receptor alpha	Rattus norvegicus	19-67
10509752-7	1999	Moreover, treatment of rat Fao cells with ciprofibrate, a peroxisome proliferator, increased the phosphorylation level of the PPARalpha.	ciprofibrate	42-54	peroxisome proliferator activated receptor alpha	Rattus norvegicus	126-135
10509752-8	1999	In addition, treatment of Fao cells with phosphatase inhibitors (okadaic acid and sodium orthovanadate) decreased the activity of ciprofibrate-induced peroxisomal acyl-coenzyme A oxidase, an enzyme encoded by a PPARalpha target gene.	ciprofibrate	130-142	peroxisome proliferator activated receptor alpha	Rattus norvegicus	211-220
10645034-0	1999	[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].	ciprofibrate	32-44	fibrinogen beta chain	Homo sapiens	133-143
10645034-1	1999	Ciprofibrate is one of the basic drugs used to lower risk values of lipid parameters and fibrinogen in atherosclerosis patients.	ciprofibrate	0-12	fibrinogen beta chain	Homo sapiens	89-99
10645034-8	1999	Ciprofibrate also significantly lowered the level of fibrinogen (-17%).	ciprofibrate	0-12	fibrinogen beta chain	Homo sapiens	53-63
10645034-11	1999	Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen.	ciprofibrate	0-12	fibrinogen beta chain	Homo sapiens	77-87
10456614-0	1999	Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.	ciprofibrate	10-22	fibrinogen beta chain	Homo sapiens	26-36
10456614-2	1999	When HepG2 cells were treated simultaneously with oncostatin M or interleukin-6 and ciprofibrate (100 nmol/l), the production of fibrinogen in the conditioned media was strongly affected and a significant decrease in the mRNA levels of the fibrinogen beta chain was observed.	ciprofibrate	84-96	fibrinogen beta chain	Homo sapiens	129-139
10456614-2	1999	When HepG2 cells were treated simultaneously with oncostatin M or interleukin-6 and ciprofibrate (100 nmol/l), the production of fibrinogen in the conditioned media was strongly affected and a significant decrease in the mRNA levels of the fibrinogen beta chain was observed.	ciprofibrate	84-96	fibrinogen beta chain	Homo sapiens	240-261
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	ciprofibrate	103-115	oncostatin M	Rattus norvegicus	0-13
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	ciprofibrate	103-115	interleukin 6	Homo sapiens	18-31
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	ciprofibrate	103-115	fibrinogen beta chain	Homo sapiens	40-50
10215695-3	1999	In the present study, we examined the effects of insulin on pyridine-, phenobarbital-, and ciprofibrate-mediated expression of CYP2E1, CYP2B, CYP3A, and CYP4A in primary cultured rat hepatocytes.	ciprofibrate	91-103	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	127-133
10402106-5	1999	There was a significant reduction in plasma fibrinogen levels (36.4 and 13.5% in the ciprofibrate and bezafibrate group, respectively).	ciprofibrate	85-97	fibrinogen beta chain	Homo sapiens	44-54
10215695-3	1999	In the present study, we examined the effects of insulin on pyridine-, phenobarbital-, and ciprofibrate-mediated expression of CYP2E1, CYP2B, CYP3A, and CYP4A in primary cultured rat hepatocytes.	ciprofibrate	91-103	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	142-147
9784004-2	1998	Ciprofibrates (racemate and both enantiomers) bind to oxidized cytochrome P-450 in rat liver microsomes according type II like aniline or most probably as inversed type I, but less pronounced and with a general shift to the left.	ciprofibrate	0-13	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	63-79
20654453-2	1998	It is demonstrated that many known peroxisome proliferators are able to occupy the putative ligand binding site of the rPPARalpha, including clofibric acid, ciprofibrate, nafenopin and related compounds.	ciprofibrate	157-169	peroxisome proliferator activated receptor alpha	Rattus norvegicus	119-129
9688458-16	1998	In rat and human PPARalpha transactivation assays, the rank order of activation was ciprofibrate > PFOA > oleic acid > or = octanoic acid > octanedioic acid or perfluorooctanol (inactive).	ciprofibrate	84-96	peroxisome proliferator activated receptor alpha	Homo sapiens	17-26
9653058-6	1998	By using the terminal transferase dUTP-biotin nick end labeling technique, it was observed that 0.1 and 0.2 mM clofibric acid and ciprofibrate suppressed transforming growth factor-beta (TGF beta)-induced apoptosis by 50% in rat hepatocytes, but they had no effect on TGF beta-induced apoptosis in human hepatocytes.	ciprofibrate	130-142	transforming growth factor, beta 1	Rattus norvegicus	187-195
9616184-8	1998	Drugs containing a carboxylic acid moiety, such as nonsteroidal anti-inflammatory agents (e.g. naproxen and ibuprofen) and fibrates (e.g. ciprofibrate), were substrates for human UGT1A3.	ciprofibrate	138-150	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	179-185
9641260-7	1998	Ciprofibrate treatment did not affect either endpoint, but catalase overexpression increased the concentrations of malondialdehyde (in untreated mice only) and conjugated dienes (in both untreated and ciprofibrate-fed mice).	ciprofibrate	201-213	catalase	Mus musculus	59-67
9653058-6	1998	By using the terminal transferase dUTP-biotin nick end labeling technique, it was observed that 0.1 and 0.2 mM clofibric acid and ciprofibrate suppressed transforming growth factor-beta (TGF beta)-induced apoptosis by 50% in rat hepatocytes, but they had no effect on TGF beta-induced apoptosis in human hepatocytes.	ciprofibrate	130-142	transforming growth factor, beta 1	Rattus norvegicus	268-276
9461014-4	1998	Furthermore, in mixed cultures exposed to 0.2 mM clofibric acid or ciprofibrate for 3 months, hepatocytes were engaged in proliferation as shown by the expression of proliferating cell nuclear antigen (PCNA) and the presence of mitotic figures.	ciprofibrate	67-79	proliferating cell nuclear antigen	Rattus norvegicus	166-200
9653058-7	1998	Although clofibric acid and ciprofibrate diminished TGF beta-induced apoptosis, they had no effect on the basal apoptotic levels in the rat hepatocyte cultures.	ciprofibrate	28-40	transforming growth factor, beta 1	Rattus norvegicus	52-60
9875418-9	1998	The combination of ciprofibrate and PGF2 alpha also significantly increased EGF, transforming growth factor-alpha (TGF-alpha) and hepatic growth factor (HGF)-induced particulate PKC activity.	ciprofibrate	19-31	transforming growth factor alpha	Rattus norvegicus	81-113
9875418-9	1998	The combination of ciprofibrate and PGF2 alpha also significantly increased EGF, transforming growth factor-alpha (TGF-alpha) and hepatic growth factor (HGF)-induced particulate PKC activity.	ciprofibrate	19-31	transforming growth factor alpha	Rattus norvegicus	115-124
9875418-9	1998	The combination of ciprofibrate and PGF2 alpha also significantly increased EGF, transforming growth factor-alpha (TGF-alpha) and hepatic growth factor (HGF)-induced particulate PKC activity.	ciprofibrate	19-31	hepatocyte growth factor	Rattus norvegicus	130-151
9875418-9	1998	The combination of ciprofibrate and PGF2 alpha also significantly increased EGF, transforming growth factor-alpha (TGF-alpha) and hepatic growth factor (HGF)-induced particulate PKC activity.	ciprofibrate	19-31	hepatocyte growth factor	Rattus norvegicus	153-156
9600348-6	1998	Ciprofibrate increased the activation of nuclear factor (NF)-kappaB in non-transgenic mice, but this increase was inhibited by catalase overexpression.	ciprofibrate	0-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	41-67
9600348-6	1998	Ciprofibrate increased the activation of nuclear factor (NF)-kappaB in non-transgenic mice, but this increase was inhibited by catalase overexpression.	ciprofibrate	0-12	catalase	Mus musculus	127-135
9513087-7	1998	Both gastrin and somatostatin mRNA abundance in antral mucosa increased markedly and significantly (P < 0.01) after ciprofibrate treatment.	ciprofibrate	119-131	gastrin	Rattus norvegicus	5-12
9513087-7	1998	Both gastrin and somatostatin mRNA abundance in antral mucosa increased markedly and significantly (P < 0.01) after ciprofibrate treatment.	ciprofibrate	119-131	somatostatin	Rattus norvegicus	17-29
9513087-9	1998	Since somatostatin mRNA abundance also increased, the present study suggests that ciprofibrate and possibly other peroxisome proliferators in sufficient concentrations have a stimulatory effect on endocrine cells.	ciprofibrate	82-94	somatostatin	Rattus norvegicus	6-18
9585093-6	1998	Western analysis revealed that COX-2 protein was induced by ciprofibrate (up to 13-fold at day 10), but that calcium-dependent (Ca-D) cPLA2 protein was not different from controls.	ciprofibrate	60-72	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-36
9585093-8	1998	Using enzyme kinetics, we found that COX-1 (Ki = 143 microM) and Ca-I cPLA2 (Ki = 121 microM) were competitively inhibited by ciprofibrate, but the inhibition was not physiologically significant.	ciprofibrate	126-138	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	37-42
9585093-8	1998	Using enzyme kinetics, we found that COX-1 (Ki = 143 microM) and Ca-I cPLA2 (Ki = 121 microM) were competitively inhibited by ciprofibrate, but the inhibition was not physiologically significant.	ciprofibrate	126-138	phospholipase A2 group IVA	Rattus norvegicus	70-75
9585093-10	1998	These results show that ciprofibrate increases Ca-I cPLA2 enzyme activity and COX-2 protein expression.	ciprofibrate	24-36	phospholipase A2 group IVA	Rattus norvegicus	52-57
9585093-10	1998	These results show that ciprofibrate increases Ca-I cPLA2 enzyme activity and COX-2 protein expression.	ciprofibrate	24-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	78-83
9461014-4	1998	Furthermore, in mixed cultures exposed to 0.2 mM clofibric acid or ciprofibrate for 3 months, hepatocytes were engaged in proliferation as shown by the expression of proliferating cell nuclear antigen (PCNA) and the presence of mitotic figures.	ciprofibrate	67-79	proliferating cell nuclear antigen	Rattus norvegicus	202-206
7676460-4	1995	Ciprofibrate treatment selectively decreased CYP1A2 mRNA expression, whereas both chemicals suppressed CYP3A2 mRNA expression.	ciprofibrate	0-12	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	45-51
9512927-6	1997	We have shown that, in the presence of PPAR alpha, the above CYP4A1 construct is transcriptionally activated by a range of structurally different peroxisome proliferators including Wy-14,643, ciprofibrate, clofibric acid and nafenopin.	ciprofibrate	192-204	peroxisome proliferator activated receptor alpha	Homo sapiens	39-49
9512927-6	1997	We have shown that, in the presence of PPAR alpha, the above CYP4A1 construct is transcriptionally activated by a range of structurally different peroxisome proliferators including Wy-14,643, ciprofibrate, clofibric acid and nafenopin.	ciprofibrate	192-204	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	61-67
9364979-0	1997	Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.	ciprofibrate	27-39	plasminogen activator, tissue type	Homo sapiens	60-93
9364979-0	1997	Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.	ciprofibrate	27-39	fibrinogen beta chain	Homo sapiens	133-143
9364979-3	1997	We sought to learn more about this variability by examining the effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in primary hyperlipidaemic patients after six and twelve weeks of treatment using different assay systems for PAI-1 and fibrinogen.	ciprofibrate	91-103	plasminogen activator, tissue type	Homo sapiens	124-157
9364979-6	1997	Fibrinogen antigen levels were elevated by 17.6% (p <0.05) and 24.3% (p <0.001) with gemfibrozil after six and twelve weeks, respectively, whereas with ciprofibrate there was no effect.	ciprofibrate	158-170	fibrinogen beta chain	Homo sapiens	0-10
9294990-12	1997	Simvastatin + ciprofibrate was more effective than pravastatin + gemfibrozil in reducing LDL, TG, and plasma fibrinogen levels.	ciprofibrate	14-26	fibrinogen beta chain	Homo sapiens	109-119
9174115-4	1997	Interestingly, treatment with a known inducer of UGT bilirubin, ciprofibrate, induced the hepatic mRNA levels encoding for the UGT1*0 isoform by 3.5-fold and for the UGT1*1 isoform by only twofold.	ciprofibrate	64-76	UDP glucuronosyltransferase 1 family, polypeptide A2	Rattus norvegicus	127-133
9174115-4	1997	Interestingly, treatment with a known inducer of UGT bilirubin, ciprofibrate, induced the hepatic mRNA levels encoding for the UGT1*0 isoform by 3.5-fold and for the UGT1*1 isoform by only twofold.	ciprofibrate	64-76	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	166-172
9013627-5	1997	The PPs Wy-14643, mono-ethylhexyl phthalate, clofibrate, ciprofibrate ethyl ester, and eicosatetraynoic acid each caused large increases in COX-2 mRNA and protein, with maximal expression seen approximately 10 h after treatment of quiescent cells.	ciprofibrate	57-69	prostaglandin-endoperoxide synthase 2	Mus musculus	140-145
8993943-10	1996	Drug combination and ciprofibrate significantly reduced plasma fibrinogen (-24 and -25%, respectively; P < 0.001) and triglycerides (-51 and -49%, respectively; P < 0.001).	ciprofibrate	21-33	fibrinogen beta chain	Homo sapiens	63-73
8993943-15	1996	CONCLUSION: Combined treatment with simvastatin and ciprofibrate effectively reduced plasma fibrinogen, triglycerides, total and LDL cholesterol and increased LDL particle size in patients with FCHL and CAD.	ciprofibrate	52-64	fibrinogen beta chain	Homo sapiens	92-102
8937853-5	1996	In contrast, treatment of cultured hepatocytes with 3 x 10(-5) M lovastatin, simvastatin, or fluvastatin increased CYP3A1/2 and CYP4A mRNA and immunoreactive protein to lower levels than those produced by treatment with 10(-5) M dexamethasone or 10(-4) M ciprofibrate.	ciprofibrate	255-267	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	115-121
8937853-8	1996	Doses of 50 or 100 mg/ kg/day fluvastatin administered for 3 days to rats increased the hepatic levels of CYP2B1/2 and CYP4A mRNA and immunoreactive protein, although to much lower levels than those produced by treatment with phenobarbital or ciprofibrate, respectively.	ciprofibrate	243-255	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	106-112
8908198-9	1996	The addition of epidermal growth factor (EGF) to the eicosanoid-ciprofibrate combination increased DNA synthesis more than EGF or the eicosanoid-ciprofibrate combination alone.	ciprofibrate	64-76	epidermal growth factor like 1	Rattus norvegicus	16-39
8908198-9	1996	The addition of epidermal growth factor (EGF) to the eicosanoid-ciprofibrate combination increased DNA synthesis more than EGF or the eicosanoid-ciprofibrate combination alone.	ciprofibrate	64-76	epidermal growth factor like 1	Rattus norvegicus	41-44
8908198-9	1996	The addition of epidermal growth factor (EGF) to the eicosanoid-ciprofibrate combination increased DNA synthesis more than EGF or the eicosanoid-ciprofibrate combination alone.	ciprofibrate	145-157	epidermal growth factor like 1	Rattus norvegicus	16-39
8908198-9	1996	The addition of epidermal growth factor (EGF) to the eicosanoid-ciprofibrate combination increased DNA synthesis more than EGF or the eicosanoid-ciprofibrate combination alone.	ciprofibrate	145-157	epidermal growth factor like 1	Rattus norvegicus	41-44
8908198-11	1996	The addition of both ciprofibrate and prostaglandins also blocked the growth inhibitory effect of transforming growth factor-beta on DNA synthesis induced by EGF.	ciprofibrate	21-33	epidermal growth factor like 1	Rattus norvegicus	158-161
8917682-0	1996	Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expression.	ciprofibrate	24-36	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	58-77
8917682-4	1996	CIPRO elevated renal CYP2E1 and CYP4A mRNA levels approximately 3- to 4-fold at 18 hr, and these levels remained elevated to 120 hr.	ciprofibrate	0-5	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	21-27
8917682-5	1996	CIPRO progressively increased renal CYP2E1 and CYP4A protein levels, so that approximately 7- and 4-fold increases, respectively, were observed at 120 hr of treatment.	ciprofibrate	0-5	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	36-42
8917682-12	1996	These results show that CIPRO-mediated, tissue-specific changes in CYP2E1 expression are not obligatorily associated with elevations in peroxisomal enzymes.	ciprofibrate	24-29	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	67-73
8615769-3	1996	Increased levels of mdr2 mRNA were observed in the liver of mice treated with different fibrates: ciprofibrate, 660+/-155% (as compared with control group); clofibrate, 611+/-77%; bezafibrate, 410+/-47%; fenofibrate, 310+/-52%; gemfibrozil, 190+/-25% (P <0.05 compared with control group).	ciprofibrate	98-110	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	20-24
7575654-5	1995	Interestingly, c-myc expression was enhanced even upon drug withdrawal, and was more stimulated by the second exposure to ciprofibrate, while c-fos expression was unaltered.	ciprofibrate	122-134	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	15-20
9364979-9	1997	After six or twelve weeks of ciprofibrate treatment, functional fibrinogen levels were decreased by 10.1% (p <0.001) and 10.5% (p <0.0001), respectively on the basis of Clauss mechanical and by 14.2% (p <0.001) and 28.2% (p <0.0001), respectively with the Clauss turbidimetric assay.	ciprofibrate	29-41	fibrinogen beta chain	Homo sapiens	64-74
21528208-3	1997	Ciprofibrate markedly induced enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, hydrogen peroxide, and to a lesser extent catalase in both control and ethanol-diet fed mice.	ciprofibrate	0-12	catalase	Mus musculus	125-133
9031453-0	1997	Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.	ciprofibrate	42-54	fibrinogen beta chain	Homo sapiens	21-31
9031453-4	1997	We studied fibrinogen levels after 12 weeks of treatment with ciprofibrate (n = 48) and gemfibrozil (n = 51) in hypercholesterolenic patients.	ciprofibrate	62-74	fibrinogen beta chain	Homo sapiens	11-21
8895482-9	1996	Serum gastrin levels measured in blood taken by vein puncture before the initiation of the drug treatment and on the last day of the 4 week treatment period, revealed a dose-related significant hypergastrinemic effect of ciprofibrate.	ciprofibrate	221-233	gastrin	Homo sapiens	6-13
8831918-5	1996	The highest activation of LPL was obtained after treatment with 200 mg ciprofibrate/day.	ciprofibrate	71-83	lipoprotein lipase	Homo sapiens	26-29
8831918-6	1996	A modest, but statistically significant, increase in HL activity was found after 100 or 200 mg ciprofibrate treatment.	ciprofibrate	95-107	lipase C, hepatic type	Homo sapiens	53-55
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	17-29	lipoprotein lipase	Homo sapiens	95-98
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	17-29	lipase C, hepatic type	Homo sapiens	103-105
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	64-76	lipoprotein lipase	Homo sapiens	95-98
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	64-76	lipase C, hepatic type	Homo sapiens	103-105
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	64-76	lipoprotein lipase	Homo sapiens	95-98
8831918-8	1996	A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters.	ciprofibrate	64-76	lipase C, hepatic type	Homo sapiens	103-105
8831919-13	1996	Furthermore, ciprofibrate reduces fibrinogen levels and benefits from a once daily regimen.	ciprofibrate	13-25	fibrinogen beta chain	Homo sapiens	34-44
8831920-2	1996	In type IIa hypercholesterolaemia, administration of 100 mg/day of ciprofibrate, to approximately 3000 patients, decreased total cholesterol (TC), triglycerides, apolipoprotein B (apo B) and low-density lipoprotein (LDL) cholesterol.	ciprofibrate	67-79	apolipoprotein B	Homo sapiens	162-178
8831920-2	1996	In type IIa hypercholesterolaemia, administration of 100 mg/day of ciprofibrate, to approximately 3000 patients, decreased total cholesterol (TC), triglycerides, apolipoprotein B (apo B) and low-density lipoprotein (LDL) cholesterol.	ciprofibrate	67-79	apolipoprotein B	Homo sapiens	180-185
8831920-4	1996	Administration of the same dose of ciprofibrate, to approximately 3500 patients with type IIb combined hyperlipidaemia, had a marked cholesterol- and triglyceride-lowering effect, in addition to producing a decrease in LDL cholesterol and apo B, and an increase in apo A-I.	ciprofibrate	35-47	apolipoprotein B	Homo sapiens	239-244
8831920-4	1996	Administration of the same dose of ciprofibrate, to approximately 3500 patients with type IIb combined hyperlipidaemia, had a marked cholesterol- and triglyceride-lowering effect, in addition to producing a decrease in LDL cholesterol and apo B, and an increase in apo A-I.	ciprofibrate	35-47	apolipoprotein A1	Homo sapiens	265-272
8625456-4	1996	Here we report that mRNA for alpha 2u-globulin, a rodent male specific protein, is markedly reduced or undetectable by Northern blot analysis of total RNA in the livers of rats treated with ciprofibrate.	ciprofibrate	190-202	alpha2u globulin	Rattus norvegicus	29-46
8625456-7	1996	The alpha 2u-globulin mRNA reappeared in the liver 2 weeks following the cessation of ciprofibrate treatment.	ciprofibrate	86-98	alpha2u globulin	Rattus norvegicus	4-21
8567672-8	1996	In transient transfection experiments, the maximum induction of luciferase expression by ciprofibrate and/or 9-cis-retinoic acid is dependent upon cotransfection of expression plasmids for PPAR alpha and RXR alpha.	ciprofibrate	89-101	peroxisome proliferator activated receptor alpha	Homo sapiens	189-199
8567672-8	1996	In transient transfection experiments, the maximum induction of luciferase expression by ciprofibrate and/or 9-cis-retinoic acid is dependent upon cotransfection of expression plasmids for PPAR alpha and RXR alpha.	ciprofibrate	89-101	retinoid X receptor alpha	Homo sapiens	204-213
7676460-5	1995	CYP4A1 mRNA expression and lauric acid hydroxylase activities were induced by ciprofibrate treatment, whereas diquat treatment moderately increased CYP4A1 mRNA levels without affecting lauric acid hydroxylase activities.	ciprofibrate	78-90	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	0-6
7676460-10	1995	Cu/Zn SOD and quinone reductase mRNA levels were increased after ciprofibrate exposure, whereas Cu/Zn SOD mRNA expression was decreased in the diquat-treated animals.	ciprofibrate	65-77	superoxide dismutase 1	Rattus norvegicus	0-9
7587954-2	1995	We examined the effects of ciprofibrate (CIPRO) and pyridine (PYR) treatment on the expression of CYP2E1, P450 4A (CYP4A), and P450 2B (CYP2B) in primary rat hepatocytes cultured on Vitrogen or Matrigel substratum and in the presence of Chee"s medium.	ciprofibrate	27-39	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	98-104
7587954-2	1995	We examined the effects of ciprofibrate (CIPRO) and pyridine (PYR) treatment on the expression of CYP2E1, P450 4A (CYP4A), and P450 2B (CYP2B) in primary rat hepatocytes cultured on Vitrogen or Matrigel substratum and in the presence of Chee"s medium.	ciprofibrate	41-46	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	98-104
7587954-4	1995	Northern blot analyses indicated that 24-hr CIPRO treatment enhanced the expression of CYP4A, and CYP2B mRNA in a concentration-dependent manner, with maximal induction of CYP2E1 mRNA (2- to 3-fold) and CYP4A1 mRNA (up to approximately 15-fold) monitored at 30-300 microM CIPRO.	ciprofibrate	44-49	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	172-178
7587954-4	1995	Northern blot analyses indicated that 24-hr CIPRO treatment enhanced the expression of CYP4A, and CYP2B mRNA in a concentration-dependent manner, with maximal induction of CYP2E1 mRNA (2- to 3-fold) and CYP4A1 mRNA (up to approximately 15-fold) monitored at 30-300 microM CIPRO.	ciprofibrate	44-49	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	203-209
7587954-8	1995	Western blot analyses revealed that 24-hr PYR (25 mM) treatment of CIPRO-treated cells, in the absence of any further increase in CYP2E1 mRNA levels, increased CYP2E1 protein levels approximately 6- to 8-fold.	ciprofibrate	67-72	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	160-166
7923586-2	1994	Ciprofibrate treatment for short-term (3 weeks) as well as long-term (12 weeks) duration increased the total cellular catalase activity, whereas superoxide dismutase (SOD) and glutathione peroxidase (GPX) activities were decreased significantly.	ciprofibrate	0-12	catalase	Homo sapiens	118-126
21556538-8	1995	CV-1 cells transiently transfected with rPPAR cDNA construct showed predominant cytoplasmic fluorescence; treatment of these cells with ciprofibrate, a peroxisome proliferator, resulted in the nuclear translocation of PPAR signal.	ciprofibrate	136-148	peroxisome proliferator activated receptor alpha	Rattus norvegicus	40-45
21556538-8	1995	CV-1 cells transiently transfected with rPPAR cDNA construct showed predominant cytoplasmic fluorescence; treatment of these cells with ciprofibrate, a peroxisome proliferator, resulted in the nuclear translocation of PPAR signal.	ciprofibrate	136-148	peroxisome proliferator activated receptor alpha	Rattus norvegicus	41-45
7735141-2	1995	D-3-hydroxybutyrate dehydrogenase EC 1.1.1.30 (BDH) activity was measured in mitochondria of rats submitted to an intermittent feeding treatment with ciprofibrate or fenofibrate, i.e. fibrate analogues with hypolipemic activity and peroxisome proliferation properties.	ciprofibrate	150-162	3-hydroxybutyrate dehydrogenase 1	Rattus norvegicus	47-50
7735141-6	1995	Incubation of hypolipemic agents (ciprofibrate, clofibrate, clobuzarit, fenofibrate or 2,4 dichlorophenoxyacetic acid) with submitochondrial linked BDH leads to an inhibition in a concentration dependent manner.	ciprofibrate	34-46	3-hydroxybutyrate dehydrogenase 1	Rattus norvegicus	148-151
7955115-1	1994	We have examined ciprofibrate and dehydroepiandrosterone (DHEA)-induced hepatic lesions for the peroxisomal beta-oxidation system enzyme peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (PBE) and its mRNA using SDS-polyacrylamide gel electrophoresis, antibodies and cDNA probe.	ciprofibrate	17-29	enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	Homo sapiens	202-205
7923586-4	1994	The observed decreases in total cellular SOD and GPX activities following ciprofibrate treatment were due to significant decreases in cytosolic CuZn SOD and GPX, whereas mitochondrial levels of Mn SOD and GPX were relatively unchanged.	ciprofibrate	74-86	superoxide dismutase 2	Homo sapiens	41-44
7923586-4	1994	The observed decreases in total cellular SOD and GPX activities following ciprofibrate treatment were due to significant decreases in cytosolic CuZn SOD and GPX, whereas mitochondrial levels of Mn SOD and GPX were relatively unchanged.	ciprofibrate	74-86	superoxide dismutase 2	Homo sapiens	194-200
7909493-10	1994	In contrast, Cip treatment greatly decreased the average number and area of persistent GGT-positive nodules, as well as the ratio between persistent GGT-positive and rGSTP1-1-positive nodules/cm2.	ciprofibrate	13-16	glutathione S-transferase pi 1	Rattus norvegicus	166-172
8031839-1	1994	Proteins from the cytochrome P-450 CYP4A gene family metabolise hormones such as prostaglandins and other fatty acids, and are induced by peroxisome proliferators such as the hypolipidaemic drugs clofibrate and ciprofibrate.	ciprofibrate	211-223	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	35-40
7909493-11	1994	Cip treatment also resulted in a 40% decrease in the average LI in the rGSTP1-1-positive nodules.	ciprofibrate	0-3	glutathione S-transferase pi 1	Rattus norvegicus	71-77
7909493-12	1994	In some rGSTP1-1-positive nodules, the LI was decreased from > 40% prior to Cip treatment to < 5% afterward, suggesting that Cip treatment interrupted progression in these nodules.	ciprofibrate	131-134	glutathione S-transferase pi 1	Rattus norvegicus	8-14
8354295-0	1993	Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of epidermal-growth-factor receptor in isolated rat hepatocytes.	ciprofibrate	0-12	epidermal growth factor receptor	Rattus norvegicus	87-119
8262913-8	1993	In mice treated with ciprofibrate, a peroxisome proliferator, a 2-fold increase in mPPAR gamma mRNA was observed in the liver and kidney.	ciprofibrate	21-33	peroxisome proliferator activated receptor gamma	Mus musculus	83-94
8354295-1	1993	Ciprofibrate, a hypolipidaemic drug with carcinogenic and peroxisome-proliferation effects in rat liver, was found to increase the phosphorylation of epidermal-growth-factor receptor in 32P-labeled isolated rat hepatocytes.	ciprofibrate	0-12	epidermal growth factor receptor	Rattus norvegicus	150-182
1282571-0	1992	Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation.	ciprofibrate	23-35	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	57-76
8318067-4	1993	Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively).	ciprofibrate	0-12	apolipoprotein B	Homo sapiens	104-113
8467241-0	1993	Effects of two peroxisome proliferators (ciprofibrate and fenofibrate) on peroxisomal membrane proteins and dihydroxyacetone-phosphate acyl-transferase activity in rat liver.	ciprofibrate	41-53	glyceronephosphate O-acyltransferase	Rattus norvegicus	108-151
8467241-1	1993	The effects of ciprofibrate and fenofibrate, which are more potent peroxisome proliferators than clofibrate, on the activities of dihydroxyacetone-phosphate acyl-transferase (DHAP-AT) and glycerol-3-phosphate acyl-transferase (G3P-AT) were studied at the two pH optima 5.5 and 7.4 in subcellular fractions of rat liver, and in solubilized peroxisomal membranes (PMP) as well.	ciprofibrate	15-27	glyceronephosphate O-acyltransferase	Rattus norvegicus	130-173
8467241-1	1993	The effects of ciprofibrate and fenofibrate, which are more potent peroxisome proliferators than clofibrate, on the activities of dihydroxyacetone-phosphate acyl-transferase (DHAP-AT) and glycerol-3-phosphate acyl-transferase (G3P-AT) were studied at the two pH optima 5.5 and 7.4 in subcellular fractions of rat liver, and in solubilized peroxisomal membranes (PMP) as well.	ciprofibrate	15-27	glyceronephosphate O-acyltransferase	Rattus norvegicus	175-182
8390885-0	1993	Stimulation of peroxisomal palmitoyl-CoA oxidase activity by ciprofibrate in hepatic cell lines: comparative studies in Fao, MH1C1 and HepG2 cells.	ciprofibrate	61-73	acyl-CoA oxidase 1	Rattus norvegicus	27-48
8425263-4	1993	Screening of another 23 ciprofibrate-induced liver tumors by oligonucleotide hybridization analysis and direct DNA sequencing resulted in the identification of three tumor DNA samples with point mutations in codon 117 of the H-ras gene.	ciprofibrate	24-36	Harvey rat sarcoma virus oncogene	Mus musculus	225-230
8499488-8	1993	In addition, the peroxisome proliferators PFDA, perfluorooctanoic acid and ciprofibrate induced hepatic ACBP following in vivo administration to rats indicating that this phenomena is not exclusive to in vitro systems.	ciprofibrate	75-87	diazepam binding inhibitor	Rattus norvegicus	104-108
1282571-1	1992	Six species (CD-1 mouse, Fischer 344 rat, Syrian golden hamster, Duncan-Hartley guinea pig, half-lop rabbit and marmoset monkey) were treated orally with ciprofibrate, a potent oxyisobutyrate hypolipidaemic drug for 14 days.	ciprofibrate	154-166	CD1 antigen complex	Mus musculus	13-17
1339049-3	1992	sEH was elevated above the normal range in at least 50% of individuals with HCC, including: 3 of 6 northern Californians; 4 of 7 Koreans with hepatitis B-associated HCC; hepatitis B-associated HCC in woodchucks; and male rats receiving chronic treatment with aflatoxin B1 or ciprofibrate.	ciprofibrate	275-287	epoxide hydrolase 2	Homo sapiens	0-3
1370768-7	1992	We have shown that during augmentative hyperplasia caused by the tumor promoters alpha-hexachlorocyclohexane, phenobarbital and ciprofibrate, plasma levels of HGF also increase.	ciprofibrate	128-140	hepatocyte growth factor	Rattus norvegicus	159-162
1561628-2	1992	Ciprofibrate was fed at concentrations ranging from 0.1 to 250 ppm to male C57BL/6N and BALB/c mice and the induction of hepatic acyl-CoA oxidase and catalase, peroxisomal enzymes involved in the formation and degradation of hydrogen peroxide, and liver hepatomegaly and mitogenesis were measured.	ciprofibrate	0-12	catalase	Mus musculus	150-158
1905530-0	1991	Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.	ciprofibrate	77-89	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	25-44
1905530-3	1991	The latter induction of cytochrome P450IVA1-dependent fatty acid hydroxylase activity was specific to this cytochrome P450 sub family, as ciprofibrate pretreatment resulted in an inhibition of the enzyme activities associated with the cytochrome P450 IIB and IA sub-families.	ciprofibrate	138-150	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	24-43
1777922-7	1991	Finally, the dual action of ciprofibrate on content and on enzymatic activity of BDH (a lipid metabolism related enzyme) reveals that such a molecule may have differential regulatory effects (positive on gene transcription or mRNA stability and negative on catalytic enzyme activity).	ciprofibrate	28-40	3-hydroxybutyrate dehydrogenase 1	Rattus norvegicus	81-84
2268348-2	1990	c-myc mRNA is highly abundant in liver and at a lower extent in kidney, especially after treatment with ciprofibrate; clofibrate also allows a c-myc mRNA increase, but at a lower extent.	ciprofibrate	104-116	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	0-5
2404574-2	1990	Ciprofibrate caused the down-regulation of five of the plasma membrane proteins (the epidermal growth factor receptor, the asialoglycoprotein receptor, HA 321, HA 4, and dipeptidylpeptidase IV) and induced the expression of a more basic, lower-Mr isoform of the basolateral plasma membrane protein CE 9.	ciprofibrate	0-12	epidermal growth factor receptor	Rattus norvegicus	85-117
2127277-2	1990	Histochemical analyses revealed a marked increase in the number, size, and catalase content of peroxisomes in the cells cultured on a medium containing 0.5 mM ciprofibrate, a peroxisome proliferator.	ciprofibrate	159-171	catalase	Rattus norvegicus	75-83
2191770-1	1990	The frequency and mutational profile of H-ras gene activation were determined in spontaneous liver tumors of male C57BL/6 x C3H/He mice and in tumors induced with the genotoxic hepatocarcinogen benzidine.2 HCl or the nongenotoxic hepatocarcinogens phenobarbital, chloroform, and ciprofibrate.	ciprofibrate	279-291	Harvey rat sarcoma virus oncogene	Mus musculus	40-45
2404574-2	1990	Ciprofibrate caused the down-regulation of five of the plasma membrane proteins (the epidermal growth factor receptor, the asialoglycoprotein receptor, HA 321, HA 4, and dipeptidylpeptidase IV) and induced the expression of a more basic, lower-Mr isoform of the basolateral plasma membrane protein CE 9.	ciprofibrate	0-12	dipeptidylpeptidase 4	Rattus norvegicus	170-192
2404574-2	1990	Ciprofibrate caused the down-regulation of five of the plasma membrane proteins (the epidermal growth factor receptor, the asialoglycoprotein receptor, HA 321, HA 4, and dipeptidylpeptidase IV) and induced the expression of a more basic, lower-Mr isoform of the basolateral plasma membrane protein CE 9.	ciprofibrate	0-12	basigin (Ok blood group)	Rattus norvegicus	298-302
2404574-3	1990	Pulse labeling, chemical deglycosylation, and 125I-wheat germ lectin blotting suggested that the ciprofibrate-induced isoform of CE 9 differed in the posttranslational modification of its oligosaccharides and contained more sialic acid.	ciprofibrate	97-109	basigin (Ok blood group)	Rattus norvegicus	129-133
2404574-7	1990	The ciprofibrate-induced decreases in the concentrations of the epidermal growth factor receptor, the asialoglycoprotein receptor, HA 321, and HA 4 were similar to the selective down-regulation of these proteins observed transiently during the period of hepatocyte proliferation following two-thirds hepatectomy.	ciprofibrate	4-16	epidermal growth factor receptor	Rattus norvegicus	64-96